Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients - Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1]- A statistically significant percentage of secukinumab-treated patients achieved 75% and 90% skin clearance at Week 12 as measured by PASI 75 and PASI 90[1]- A majority of secukinumab-treated patients achieving PASI 75 responses at Week 12 also maintained the response at Week 52 with continued treatment[1]

EAST HANOVER, N.J., July 9, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published the results from two pivotal Phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab (AIN457). Secukinumab met all primary and key secondary endpoints in the ERASURE and FIXTURE studies, including Psoriasis Area and Severity Index (PASI) 75 and 90 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 responses.[1] The results of the studies are the first Phase III data for an IL-17A inhibitor to be published in a major scientific journal and were part of the data submitted to the FDA, with action expected early next...